share_log

HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

Benzinga ·  Feb 29 15:21

HC Wainwright & Co. analyst Mitchell Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $8 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment